title: [Raynaud's phenomenon: effects of terazosin].
abstract: After considering the clinical and physiopathological aspects of Raynaud's phenomenon, the authors have evaluated the medium effects of therazosine in 2 groups of patients, respectively with idiopathic and secondary Raynaud's phenomenon. The results show that the therazosin determines a decrease of number, intensity and duration of vasospastic attacks to the hands as well as an improvement of telethermographic and ultrasonographic findings.
authors.affiliation: Istituto di Patologia Medica, Università degli Studi, Palermo.
authors.forename: S
authors.initials: S
authors.lastname: Paterna
authors.forename: A
authors.initials: A
authors.lastname: Pinto
authors.forename: A
authors.initials: A
authors.lastname: Arrostuto
authors.forename: M G
authors.initials: MG
authors.lastname: Cannavò
authors.forename: P
authors.initials: P
authors.lastname: Di Pasquale
authors.forename: C
authors.initials: C
authors.lastname: Cottone
authors.forename: G
authors.initials: G
authors.lastname: Licata
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011224:Prazosin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011928:Raynaud Disease / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology; D014463:Ultrasonography
chemical_list: D000317:Adrenergic alpha-Antagonists; C041226:Terazosin; D011224:Prazosin